Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial
Kalifa Bojang(MRC Unit the Gambia), Tom Doherty(MRC Unit the Gambia), Brian Greenwood(MRC Unit the Gambia), Adrian V. S. Hill(University of Oxford), Nadia Tornieporth(GlaxoSmithKline (United Kingdom)), Martine Delchambre(GlaxoSmithKline (United Kingdom)), Paul Milligan(MRC Unit the Gambia), Laurence Vigneron(GlaxoSmithKline (United Kingdom)), Philip Gothard(John Radcliffe Hospital), Ali Alloueche(London School of Hygiene & Tropical Medicine), Gérald Voss(TuBerculosis Vaccine Initiative), Kent E. Kester(Walter Reed Army Institute of Research), Lawrence Yamuah(MRC Unit the Gambia), W. Ripley Ballou(Walter Reed Army Institute of Research), Keith P. W. J. McAdam(London School of Hygiene & Tropical Medicine), Margaret Pinder(MRC Unit the Gambia), William H. H. Reece(John Radcliffe Hospital), David J. Conway, Joe Cohen(GlaxoSmithKline (United Kingdom))
Cited by 528
Related Papers
Bulletin of the World Health Organization
|Bulletin of the World Health Organization|2001|7.2k
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
|Nature Medicine|2020|643